Bisabolol: nineteen varieties in profiles, none in the pharmacy list

What is bisabolol and where is it found outside of hemp?

Bisabolol is a sesquiterpene alcohol with the formula C15H26O and a molecular weight of 222.37, known in cosmetics as lewomenol. Outside of hemp, it is primarily responsible for the composition of the essential oil from common chamomile, where it can be a main ingredient. In hemp, it is one of the compounds detected rarely and in small amounts, not among those that define the character of the strain.

In terms of structure, it is a molecule with fifteen carbon atoms and one hydroxyl group attached to a tertiary carbon. The form found in nature is usually alpha-(-)-bisabolol, and the cosmetic industry also uses the racemate obtained synthetically. The commercial name lewomenol refers to the same compound, but in the context of topical preparations.

The plant most strongly associated with the compound is common chamomile: bisabolol accounts for a significant portion of the oil obtained from its flower heads. It has also been described in the oils of other species, such as Myoporum crassifolium. In hemp, it remains a secondary component, as evidenced by our data: pharmacy labels that feature this cluster fill the leading terpene field with only six names, and bisabolol is not among them even once. It only entered the collection from profile databases that describe the strain more broadly than the product label.

Two things can easily be confused here. The name of the terpene describes the chemical compound, not the effect of the preparation in which this compound is found. The cosmetic use of lewomenol pertains to topical application and does not indicate what happens after inhaling vapor from heated dried flower.

How long does it take for bisabolol to reach the body and how long does it stay there?

It is unknown. For bisabolol itself, there is no published measurement of concentrations in humans after vaporizing dried flower, so the answer can only be provided for the route of administration, not for the compound. Boiling point temperatures from chemical tables do not answer this question either. The following description pertains to the course after vaporization and after ingestion.

The route of administration determines the course more than the variety itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two hours, and the episode can last six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks nothing is happening after thirty minutes and takes another dose will receive both doses at once. The above ranges describe the route of administration, not this variety; pharmacokinetic studies for a single cultivar have not been published.

The question of temperature stands separately. In the collection of boiling points constructed for this cluster, there is not a single measurement for bisabolol: a query to the public database PubChem for detailed data returned an error, and the field was left empty. Of the eleven terpenes in the project, only six have boiling points provided along with pressure. Humulene has only a measurement under reduced pressure, 99.5 degrees Celsius at 3 mmHg, which is a number that cannot be compared to a measurement at ambient pressure. Nerolidol and ocimene have records without specified pressure, so they also do not enter any comparison.

The boiling point of a pure substance is not the setting of the device and does not indicate how much of the compound reaches the vapor or how much from the vapor enters the blood. Therefore, we do not provide a range of settings or methods of intake here: such numbers are not contained in our sources, and an invented number looks exactly the same on the page as a measured one.

What have studies shown about the effects of bisabolol?

Two studies, both on mice, both with oral administration. The earlier one concerns chemically induced pain responses, while the newer one addresses arthritis induced by an adjuvant. Neither included humans, and neither administered the compound via inhalation, so they are only connected by the name of the substance. What happens in humans cannot be inferred from them.

Both studies share the same limitation of the model. The animal was a mouse, and the substance was administered to the gastrointestinal tract, so the described course pertains to the animal after ingesting the preparation dissolved in a carrier, not to a human inhaling vapor from heated dried flower. The newer study adds a second thread: the researchers compared the compound itself with its complex with beta-cyclodextrin, meaning they were looking for a way to improve the behavior of the substance in the body. Such a comparison is made when the original form poses a problem.

The evidence base for the entire cluster consists of 22 studies divided among eleven terpenes. None included humans. Two do not concern any mammal: they describe a plant and an insect, and one of this pair is a review of insect literature. The remaining studies involve rodents or cell cultures. With such material, a statement about what the terpene does to a patient would not be supported by the source, and therefore it is not made in this text.

The doses in the earlier study were given in milligrams per kilogram of animal body weight. Translating them into a dose of dried flower would require two things we do not have: measurement of the compound's content in a specific batch of the product and data on how much of it passes into vapor when heated. Without these two numbers, transferring the result to humans remains a guess.

What has not been shown about bisabolol?

No study in humans has examined bisabolol derived from hemp flower. In the earlier of the two studies on mice, the analgesic effect was not dose-dependent, which is a warning sign for an active substance, not a confirmation of effect. Both gaps are separate, and neither is closed by referencing the other study.

The lack of dose dependence is the most serious objection in this study. An active substance usually behaves such that a larger dose produces a stronger effect, at least up to saturation. When three different doses yield the same result, explanations unrelated to pharmacology become equally plausible: a general change in the animal's behavior, the involvement of the carrier, or the sensitivity of the test itself. This does not prove that the compound remains inactive. However, it closes the door to the simplest conclusion that popular texts draw from this study.

The second gap is broader and concerns the entire route of administration. No study has been published in which humans were given bisabolol derived from hemp flower, which is precisely the situation a patient in a pharmacy is asking about. There is also no measurement of how much of the compound remains in the vapor after heating the dried flower, nor a measurement of its concentration in the blood after vaporization. The missing links form a chain: without the first of them, the other two have nothing to transfer.

We also have no reports of adverse effects attributed solely to bisabolol or descriptions of interactions with drugs for this single compound. Additionally, there is a lack on the market side: in our pharmacy list, no entry indicates it as a leading terpene, so there is not even a group of patients taking a strain described by this name. The entire picture is based on two studies on mice, and it should be read as such.

What adverse effects have been reported after this terpene?

There is not a single report regarding bisabolol in our sources. Adverse event reports are registered for medicinal products, not for individual components of the oil, so there are no statistics associated with the name of this compound. The following description pertains to dried flower as a group of raw materials, as data exists only at this level.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

There is also a caveat regarding the terpenes themselves. At high concentrations, they can be irritating to the respiratory tract and skin, and the vapor from heated dried flower carries them along with other volatile components. However, our sources do not separate reports by individual compounds, so it is impossible to determine what corresponds to bisabolol and what to anything else in this mixture.

Cosmetic experience with lewomenol does not replace this data. A product applied to the skin and vapor inhaled into the lungs are two different routes of administration, and safety established for one does not transfer to the other. If a symptom appears after changing strains, the report should be directed to the attending physician or to the adverse event reporting system, as that is where the product's batch number goes.

Which strains from Polish pharmacies have bisabolol as the leading terpene?

None. In the pharmacy list where this cluster is located, none of the 85 entries has bisabolol indicated as the leading terpene, as the labels only mention six names. However, profile databases show it in the composition of nineteen strains. These two lists are not the same, and one does not replace the other.

The pharmacy list describes 85 cultivars in 141 registration entries. The leading terpene field contains only six values visible in the table above, and bisabolol does not appear in this field even once. This is a limitation of the source, not a measurement result: the product label mentions one compound, not the full composition of the oil.

Profile databases go further and indicate bisabolol in the composition of nineteen out of 85 cultivars. This is a different claim than leading participation: it states that the compound was detected in the profile, not that it gives the strain character. On this list are Beach Crasher, Blueberry, Frosted Lemon Angel, Galaxy Walker OG, Gorilla Glue, Headband, Island Sweet Skunk, Jean Guy, Lilac Diesel, Mac Monkey (Blue Monkey), Master Kush, Pink Kush, Purps, Rockstar, Sirius, Sourdough, Tilray Sirius, Wedding Pie and White Widow.

The list changes with availability, as registered items come into circulation and disappear from it, and permits expire. The current state collects a cluster strain hub. Store category of dried flower includes a different mode of circulation than the raw material described here from the Rpw category and should not be confused with the pharmacy list.

Why don't we provide the bisabolol content in the strain profile?

Because the denominator is unknown. In the records of one database, where bisabolol is mentioned at all, the sum of all reported contents goes down to 14 and reaches 102, with a median of 84. If these numbers described the same whole, each sum would yield the same value. The second database does not provide any numbers for terpenes.

The material for this calculation comes from the tables of one profiling source. Bisabolol appears in such a table in 60 records out of 146, and the sums of declared contents take on 25 different values. Two records exceed one hundred, which is arithmetically impossible for the contents of one whole. Therefore, the denominator is not only unknown: it can vary within the same source.

The position of the compound in the ranking is, however, stable information, and we provide that. In none of these 60 records does bisabolol rank first. At most, it reaches third place in 19 records, falls to fourth in 14, and is lower in the remaining ones. The second source provides only the weighted order without numbers, and there bisabolol ranks third in three out of five descriptions.

Hence our rule. We state that a compound is present in the profile and its position, not how much of it there is. A number without a denominator in a text about a prescription medication looks like a measurement, but it is not a measurement, since two sources would count it differently.

Do the profile databases agree on the presence of bisabolol?

No. Among the nineteen strains containing bisabolol, eleven are described by only one source, and for the remaining eight, both sources provide different compositions. The discrepancy also runs across a single database: its list of markers and its share table do not say the same thing. This difference is not a reading error.

For the eight strains described by both sources, the distribution looks like this. In three cases, bisabolol is indicated exclusively by the first source (Gorilla Glue, Beach Crasher, and Lilac Diesel), in one exclusively by the second (Wedding Pie), and in the remaining four by both (Pink Kush, Galaxy Walker OG, Island Sweet Skunk, and Purps). Therefore, full agreement pertains to a minority of cases.

Within one source, the picture is also inconsistent. In the database with share tables, 49 entries mention bisabolol simultaneously on the list of markers and in the number table, while 11 entries have it exclusively in the table. The reverse arrangement does not occur even once. For five strains, the compound does not appear on the list of markers in any entry, so in the compilation built from markers, these strains do not appear at all.

Contradictions can even arise between two entries of the same strain in the same database: for seven strains, the entries differ from each other, and Triangle Mints has two descriptions, one of which lists bisabolol in the table, while the other omits it. Therefore, the number of nineteen strains is a figure from one field of one source, not a factual state of the plant, and we present it with this caveat.

Frequently Asked Questions

Has bisabolol from hemp been studied in humans?

No. Both studies on this compound in our evidence base were conducted on mice, with oral administration, and neither included humans or inhalation.

Does any pharmaceutical strain have bisabolol as the leading terpene?

No. None of the 85 entries in our list indicates bisabolol as the leading terpene, as pharmaceutical labels fill this field with only six names.

In how many strains do the profile databases indicate bisabolol in the composition?

In nineteen out of 85 cultivars. Eleven of them are described by only one source, and for the remaining eight, both sources provide different compositions.

At what temperature does bisabolol evaporate?

Our data does not provide this information: the record for bisabolol in the boiling points collection has no measurement. The boiling point of the pure substance is not the setting of the device.

Is bisabolol from chamomile the same compound as in hemp?

Yes, it refers to the same sesquiterpene alcohol with the formula C15H26O. Our collection reads it as alpha-bisabolol, and the form found in nature differs isomerically from the racemate obtained synthetically.

What side effects have been described after bisabolol alone?

None in our sources. Reports are collected for medicinal products with a batch number, so under the name of a single terpene, there is no separate statistic.

Why do you not provide the share of bisabolol in the profile?

Because the sums of declared shares in one source go down to 14 and reach 102 with a median of 84, so the denominator is unknown, and the second source does not provide any numbers for terpenes.

Dried flower is a pharmaceutical raw material dispensed by prescription in the Rpw category. The material is informational in nature, describes the state of evidence, and does not replace medical advice or treatment decisions.

Editorial text: redakcja ubucha.pl.